These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 17596994

  • 1. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G.
    Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
    Mendelsohn J, Baselga J.
    J Clin Oncol; 2003 Jul 15; 21(14):2787-99. PubMed ID: 12860957
    [Abstract] [Full Text] [Related]

  • 8. Targeting epidermal growth factor receptor in head and neck cancer.
    Ford AC, Grandis JR.
    Head Neck; 2003 Jan 15; 25(1):67-73. PubMed ID: 12478546
    [Abstract] [Full Text] [Related]

  • 9. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
    Forsberg S, Ostman A, Rollman O.
    Arch Dermatol Res; 2008 Oct 15; 300(9):505-16. PubMed ID: 18446355
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O, Bozec A, Fischel JL, Milano G.
    Crit Rev Oncol Hematol; 2007 Apr 15; 62(1):53-61. PubMed ID: 17324578
    [Abstract] [Full Text] [Related]

  • 13. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A, Vidal L, Shaw H, de Bono J.
    Eur J Cancer; 2007 Feb 15; 43(3):481-9. PubMed ID: 17208435
    [Abstract] [Full Text] [Related]

  • 14. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R.
    Biochem Biophys Res Commun; 2004 Jun 18; 319(1):1-11. PubMed ID: 15158434
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
    Patel JD.
    Curr Opin Oncol; 2006 Nov 18; 18(6):609-14. PubMed ID: 16988582
    [Abstract] [Full Text] [Related]

  • 16. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F, Lee HY.
    Drug Resist Updat; 2005 Oct 18; 8(5):298-310. PubMed ID: 16172017
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.
    Kelloff GJ, Fay JR, Steele VE, Lubet RA, Boone CW, Crowell JA, Sigman CC.
    Cancer Epidemiol Biomarkers Prev; 1996 Aug 18; 5(8):657-66. PubMed ID: 8824370
    [Abstract] [Full Text] [Related]

  • 18. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.
    Arteaga CL.
    J Clin Oncol; 2001 Sep 15; 19(18 Suppl):32S-40S. PubMed ID: 11560969
    [Abstract] [Full Text] [Related]

  • 19. EGFR as a target: rationale for therapy.
    Wujcik D.
    Semin Oncol Nurs; 2006 Feb 15; 22(1 Suppl 1):5-9. PubMed ID: 16616281
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.